Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4560736 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| LY4560736 Part A: Single-Ascending Dose (SAD) | EXPERIMENTAL | LY4560736 administered intravenously (IV) or subcutaneously (SC) in healthy volunteers. |
| Placebo Part A | PLACEBO_COMPARATOR | Placebo administered IV or SC in healthy volunteers. |
| LY4560736 Part B: Multiple Ascending Dose (MAD) | EXPERIMENTAL | LY4560736 administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid positron emission tomography (PET) scan. |
| Placebo Part B | PLACEBO_COMPARATOR | Placebo administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid PET scan. |
| Name | Type | Description |
|---|---|---|
| LY4560736 | DRUG | Administered intravenously (IV) |
| Placebo | DRUG | Administered IV |
| Florbetapir F18 | OTHER | Administered IV |
| Florbetaben F 18 | OTHER | Administered IV |
Inclusion Criteria: * Participants must meet eligibility criteria in the A1D-MC-ATMP screening protocol before entry into the treatment study. * To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participant's biologic...
Top 20 of 31 competitors
LY4560736 is an investigational small molecule being developed by Eli Lilly and Company for Alzheimer disease. It is in Phase 1 clinical development and has not been approved by the FDA. It is being studied in healthy participants as well as participants with Alzheimer disease.
LY4560736 is being studied as a potential treatment for Alzheimer disease. The Phase 1 program also enrolls healthy volunteers, and trial conditions include amyloid plaque and plasma amyloid measures. It is investigational, meaning it is not approved for any use and remains in clinical development.
LY4560736 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 study evaluating the compound in healthy participants and participants with Alzheimer disease.
LY4560736 is in Phase 1 clinical development. One Phase 1 trial is registered and is currently active, with a status of not yet recruiting. No Phase 2 or Phase 3 studies have been registered, and the drug is not FDA approved.
LY4560736 is being evaluated in one registered Phase 1 trial, NCT07843459, titled A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease. The trial is randomized, double blind, and placebo controlled, plans to enroll 111 participants, and is being run in the United States, China, and Japan.